Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Hematopoiesis01:20

Overview of Hematopoiesis

4.9K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
4.9K
Hematopoiesis01:21

Hematopoiesis

5.7K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.7K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

509
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
509
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

1.7K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physician-pharmacy integration in cancer care: pillars of medically integrated pharmacy.

The American journal of managed care·2026
Same author

AMCP Market Insights: Managed care approaches to bispecific antibodies with a focus on follicular lymphoma and diffuse large B-cell lymphoma.

Journal of managed care & specialty pharmacy·2025
Same author

Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia.

Journal of managed care & specialty pharmacy·2025
Same author

Impact of melphalan day -1 vs day -2 on outcomes after autologous stem cell transplant for multiple myeloma.

Frontiers in immunology·2024
Same author

Erdafitinib's Road to Approval and Use in Urothelial Carcinoma.

Oncology (Williston Park, N.Y.)·2023
Same author

2021-2022 Drug Updates in Solid Tumors.

Journal of the advanced practitioner in oncology·2023

Related Experiment Video

Updated: Sep 20, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.3K

2020-2021 Drug Updates in Hematologic Malignancies.

Kirollos Hanna1

  • 1M Health Fairview and Mayo Clinic College of Medicine, Maple Grove, Minnesota.

Journal of the Advanced Practitioner in Oncology
|June 6, 2022
PubMed
Summary

Advanced practitioners can now safely manage hematologic malignancies with newly approved therapies. This includes CAR T-cell therapies, PI3K inhibitors, and immunotherapies, offering new treatment options.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Recent advancements in cancer therapeutics have led to novel drug and biologic approvals.
  • Managing patients with hematologic malignancies requires up-to-date knowledge of emerging treatments.

Purpose of the Study:

  • To review the label indications of drugs and biologics approved for hematologic malignancies between late 2020 and late 2021.
  • To provide advanced practitioners with information on mechanisms of action and safety profiles of new therapeutic agents.

Main Methods:

  • Review of drug and biologic approvals for hematologic malignancies.
  • Discussion of mechanisms of action and safety profiles.
  • Focus on therapies approved from late 2020 to late 2021.

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.8K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.1K

Related Experiment Videos

Last Updated: Sep 20, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.3K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.8K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.1K

Main Results:

  • Several new therapeutic agents were approved for hematologic malignancies.
  • Chimeric antigen receptor (CAR) T-cell therapies received approvals across multiple hematologic cancers.
  • Other approved agents include phosphoinositide 3-kinase (PI3K) inhibitors, anti-CD38 monoclonal antibodies, and novel immunotherapies.

Conclusions:

  • Advanced practitioners must stay informed about new approvals to optimize patient care.
  • Understanding the specific indications, mechanisms, and safety of these agents is crucial for effective management.
  • The reviewed therapies represent significant progress in treating hematologic malignancies.